slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
UBS 22 ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE FEBRUARY 2012 PowerPoint Presentation
Download Presentation
UBS 22 ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE FEBRUARY 2012

Loading in 2 Seconds...

play fullscreen
1 / 17

UBS 22 ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE FEBRUARY 2012 - PowerPoint PPT Presentation


  • 89 Views
  • Uploaded on

UBS 22 ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE FEBRUARY 2012. PREMIER global preclinical services provider. World-class preclinical service provider offering unparalleled expertise and expert scientific staff providing services from early discovery to IND filing and beyond

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'UBS 22 ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE FEBRUARY 2012' - bryce


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

UBS

22ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE

FEBRUARY 2012

premier global preclinical services provider
PREMIER global preclinical services provider
  • World-class preclinical service provider offering unparalleled expertise and expert scientific staff providing services from early discovery to IND filing and beyond
  • Global operations in North America, Europe and Asia with 750 dedicated staff
  • Integrated discovery and development capabilities to accelerate compounds to the clinic

Asia

Europe

United States

ricerca services continuum
RICERCA SERVICES CONTINUUM

Target Identification

HTS (High Throughput Screening)

Hit Identification

Hit to Lead

Lead Optimization (SAR)

Preclinical Candidate Selection

IND Enabling & Registration Support Studies

API & Commercial Scale-Up

Clinical Candidate

Phase I - III

NDA

Market Introduction

global locations
GLOBAL LOCATIONS

Asia

North

America

Europe

Lyon, France

Concord, Ohio

Taipei, Taiwan

Bothell, WA

what s going on in the pharmaceutical industry

WHAT’S GOING ON IN THE PHARMACEUTICAL INDUSTRY?

Internal & External (Licensing) ‘push’ for clinical candidates

Unprecedented removal of competent, but costly, drug development infrastructure and people

Realization of a ‘data gap’ in early clinical programs from academia and biotechnology sector

“Risk Capital” for biotechnology from venture pools evaporated in mid-2008

The bar is set much higher for drug candidate approvals and commercial acceptance

consequences of industry change
CONSEQUENCES OF INDUSTRY CHANGE
  • Proliferation of Pharma licensing and M&A deals in biotechnology (PharmAsset, Inhibitex) for early clinical assets
  • Externalization of research (pre-IND) and development (clinical development)
  • Data, timelines and quality gaining momentum over cost of outsourcing services (price) that has been severe in 2009-2011
  • Global Pharma replacing private venture, but that will change in 2012 with valuation potentials
what do our clients need
WHAT DO OUR CLIENTS NEED?
  • Specific ‘a la carte’ R&D local and global capabilities that translate into trusted, highly reproducible and timely data
  • Solutions in the form of programs and packages for several steps in drug research-integrated service offerings
  • Therapeutic expertise
  • Trust, not promises. A partner, not a marriage
outsourcing research industry
OUTSOURCING RESEARCH INDUSTRY
  • Pricing pressure and reduced pre clinical development candidates (since 4Q 2008) have resulted in over capacity and loss of scientific talents in CROs
  • Consolidation: but it has just begun
  • Rise of China: Fall of China-Rise of Asia
  • Changing business models
  • Demands for innovation unclear
ricerca strategy
RICERCA STRATEGY
  • Best of “Best in Class” discovery pharmacology a la carte capabilities in Europe, U.S. and Asia (Taiwan)
  • Integrated IND “packaged solutions” for biotechnology clients and recently global pharmaceutical clients (chemistry, in vivo, in vitro, safety assessment studies)
  • Client satisfaction
  • Regulatory (CAPA) compliance
  • Acquisitive Management Team
diversified client mix
DIVERSIFIED CLIENT MIX

Top 10

Client Mix

2012 outsourcing market 20b
2012 OUTSOURCING MARKET ($20B)

Source: Goldman Sachs Investment Research citing CRO Company data, IMS Health, PhRMA, Ernest & Young

the results
THE RESULTS
  • Global capabilities in Europe, U.S. and Asia
  • Leadership in Discovery Pharmacology
  • Great client mix, distribution of geographies and no single client dependencies
  • Highest client satisfaction rating, >95%
  • Growth in revenues and assets
  • Minimal debt
slide17

UBS

22ND ANNUAL GLOBAL HEALTHCARE SERVICES CONFERENCE

FEBRUARY 2012